Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer

Elaina Susan Renata Collie-Duguid, S. J. Johnston, L. Boyce, Natalie Smith, Aaron Cowieson, J. Cassidy, Graeme Ian Murray, H. L. McLeod

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

It is essential for actively proliferating cells to increase their rate of DNA synthesis to progress through the cell cycle. This is reflected in the increased uracil usage that is a common feature in solid tumours. Thymidine phosphorylase (TP) anabolises formation of pyrimidine nucleosides available for DNA synthesis, whereas dihydropyrimidine dehydrogenase (DPD) catabolises the degradation of pyrimidine bases, thereby reducing levels of uracil and thymine available for DNA synthesis. In addition, tissue levels of TP or DPD have been associated with the clinical efficacy of pyrimidine antimetabolites commonly used in the treatment of colorectal cancer. There is little information, however, on the relative expression or degree of co-ordinated regulation of either protein in primary or metastatic colorectal cancer. DPD and TP protein levels were measured in 15 primary colorectal carcinomas, 10 colorectal liver metastases and 25 adjacent uninvolved tissues. DPD was reduced in 67% (10/15) of colorectal tumours (mean tumour/normal=0.52) and in all liver metastases (mean tumour/normal=0.41) compared with the corresponding normal tissue. In contrast, TP was increased in 80% (12/15) of colorectal tumours (mean tumour/normal=18.91) and in all metastases (mean tumour/normal=3.70). TP and DPD protein expression were highly variable in uninvolved and tumour tissues. The ratio of TP: DPD was higher in 87% of colorectal tumours and in all liver metastases compared with the adjacent uninvolved tissues. This suggests the presence of co-ordinated regulation of these pyrimidine metabolic enzymes and offers a strategy for optimising the use of pyrimidine-based chemotherapy. (C) 2001 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)297-301
Number of pages4
JournalInternational Journal of Cancer
Volume94
Issue number2
DOIs
Publication statusPublished - Aug 2001

Keywords

  • thymidine phosphorylase
  • dihydropyrimidine dehydrogenase
  • colorectal cancer
  • EPITHELIAL OVARIAN-CANCER
  • CELL GROWTH-FACTOR
  • GENE-EXPRESSION
  • ANGIOGENIC FACTOR
  • 5-FLUOROURACIL
  • TUMORS
  • CHEMOTHERAPY
  • XENOGRAFTS
  • CARCINOMA
  • FLUOROPYRIMIDINES

Cite this

Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. / Collie-Duguid, Elaina Susan Renata; Johnston, S. J.; Boyce, L.; Smith, Natalie; Cowieson, Aaron; Cassidy, J.; Murray, Graeme Ian; McLeod, H. L.

In: International Journal of Cancer, Vol. 94, No. 2, 08.2001, p. 297-301.

Research output: Contribution to journalArticle

Collie-Duguid, Elaina Susan Renata ; Johnston, S. J. ; Boyce, L. ; Smith, Natalie ; Cowieson, Aaron ; Cassidy, J. ; Murray, Graeme Ian ; McLeod, H. L. / Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. In: International Journal of Cancer. 2001 ; Vol. 94, No. 2. pp. 297-301.
@article{7332c4219e05468b9541b0a7b4e0b58e,
title = "Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer",
abstract = "It is essential for actively proliferating cells to increase their rate of DNA synthesis to progress through the cell cycle. This is reflected in the increased uracil usage that is a common feature in solid tumours. Thymidine phosphorylase (TP) anabolises formation of pyrimidine nucleosides available for DNA synthesis, whereas dihydropyrimidine dehydrogenase (DPD) catabolises the degradation of pyrimidine bases, thereby reducing levels of uracil and thymine available for DNA synthesis. In addition, tissue levels of TP or DPD have been associated with the clinical efficacy of pyrimidine antimetabolites commonly used in the treatment of colorectal cancer. There is little information, however, on the relative expression or degree of co-ordinated regulation of either protein in primary or metastatic colorectal cancer. DPD and TP protein levels were measured in 15 primary colorectal carcinomas, 10 colorectal liver metastases and 25 adjacent uninvolved tissues. DPD was reduced in 67{\%} (10/15) of colorectal tumours (mean tumour/normal=0.52) and in all liver metastases (mean tumour/normal=0.41) compared with the corresponding normal tissue. In contrast, TP was increased in 80{\%} (12/15) of colorectal tumours (mean tumour/normal=18.91) and in all metastases (mean tumour/normal=3.70). TP and DPD protein expression were highly variable in uninvolved and tumour tissues. The ratio of TP: DPD was higher in 87{\%} of colorectal tumours and in all liver metastases compared with the adjacent uninvolved tissues. This suggests the presence of co-ordinated regulation of these pyrimidine metabolic enzymes and offers a strategy for optimising the use of pyrimidine-based chemotherapy. (C) 2001 Wiley-Liss, Inc.",
keywords = "thymidine phosphorylase, dihydropyrimidine dehydrogenase, colorectal cancer, EPITHELIAL OVARIAN-CANCER, CELL GROWTH-FACTOR, GENE-EXPRESSION, ANGIOGENIC FACTOR, 5-FLUOROURACIL, TUMORS, CHEMOTHERAPY, XENOGRAFTS, CARCINOMA, FLUOROPYRIMIDINES",
author = "Collie-Duguid, {Elaina Susan Renata} and Johnston, {S. J.} and L. Boyce and Natalie Smith and Aaron Cowieson and J. Cassidy and Murray, {Graeme Ian} and McLeod, {H. L.}",
year = "2001",
month = "8",
doi = "10.1002/ijc.1462",
language = "English",
volume = "94",
pages = "297--301",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer

AU - Collie-Duguid, Elaina Susan Renata

AU - Johnston, S. J.

AU - Boyce, L.

AU - Smith, Natalie

AU - Cowieson, Aaron

AU - Cassidy, J.

AU - Murray, Graeme Ian

AU - McLeod, H. L.

PY - 2001/8

Y1 - 2001/8

N2 - It is essential for actively proliferating cells to increase their rate of DNA synthesis to progress through the cell cycle. This is reflected in the increased uracil usage that is a common feature in solid tumours. Thymidine phosphorylase (TP) anabolises formation of pyrimidine nucleosides available for DNA synthesis, whereas dihydropyrimidine dehydrogenase (DPD) catabolises the degradation of pyrimidine bases, thereby reducing levels of uracil and thymine available for DNA synthesis. In addition, tissue levels of TP or DPD have been associated with the clinical efficacy of pyrimidine antimetabolites commonly used in the treatment of colorectal cancer. There is little information, however, on the relative expression or degree of co-ordinated regulation of either protein in primary or metastatic colorectal cancer. DPD and TP protein levels were measured in 15 primary colorectal carcinomas, 10 colorectal liver metastases and 25 adjacent uninvolved tissues. DPD was reduced in 67% (10/15) of colorectal tumours (mean tumour/normal=0.52) and in all liver metastases (mean tumour/normal=0.41) compared with the corresponding normal tissue. In contrast, TP was increased in 80% (12/15) of colorectal tumours (mean tumour/normal=18.91) and in all metastases (mean tumour/normal=3.70). TP and DPD protein expression were highly variable in uninvolved and tumour tissues. The ratio of TP: DPD was higher in 87% of colorectal tumours and in all liver metastases compared with the adjacent uninvolved tissues. This suggests the presence of co-ordinated regulation of these pyrimidine metabolic enzymes and offers a strategy for optimising the use of pyrimidine-based chemotherapy. (C) 2001 Wiley-Liss, Inc.

AB - It is essential for actively proliferating cells to increase their rate of DNA synthesis to progress through the cell cycle. This is reflected in the increased uracil usage that is a common feature in solid tumours. Thymidine phosphorylase (TP) anabolises formation of pyrimidine nucleosides available for DNA synthesis, whereas dihydropyrimidine dehydrogenase (DPD) catabolises the degradation of pyrimidine bases, thereby reducing levels of uracil and thymine available for DNA synthesis. In addition, tissue levels of TP or DPD have been associated with the clinical efficacy of pyrimidine antimetabolites commonly used in the treatment of colorectal cancer. There is little information, however, on the relative expression or degree of co-ordinated regulation of either protein in primary or metastatic colorectal cancer. DPD and TP protein levels were measured in 15 primary colorectal carcinomas, 10 colorectal liver metastases and 25 adjacent uninvolved tissues. DPD was reduced in 67% (10/15) of colorectal tumours (mean tumour/normal=0.52) and in all liver metastases (mean tumour/normal=0.41) compared with the corresponding normal tissue. In contrast, TP was increased in 80% (12/15) of colorectal tumours (mean tumour/normal=18.91) and in all metastases (mean tumour/normal=3.70). TP and DPD protein expression were highly variable in uninvolved and tumour tissues. The ratio of TP: DPD was higher in 87% of colorectal tumours and in all liver metastases compared with the adjacent uninvolved tissues. This suggests the presence of co-ordinated regulation of these pyrimidine metabolic enzymes and offers a strategy for optimising the use of pyrimidine-based chemotherapy. (C) 2001 Wiley-Liss, Inc.

KW - thymidine phosphorylase

KW - dihydropyrimidine dehydrogenase

KW - colorectal cancer

KW - EPITHELIAL OVARIAN-CANCER

KW - CELL GROWTH-FACTOR

KW - GENE-EXPRESSION

KW - ANGIOGENIC FACTOR

KW - 5-FLUOROURACIL

KW - TUMORS

KW - CHEMOTHERAPY

KW - XENOGRAFTS

KW - CARCINOMA

KW - FLUOROPYRIMIDINES

U2 - 10.1002/ijc.1462

DO - 10.1002/ijc.1462

M3 - Article

VL - 94

SP - 297

EP - 301

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -